N-PORT filing recap · October 2022

What did ARK Genomic Revolution ETF buy in October 2022?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$2.34B

Positions

Estimated turnover

24.3%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

NVDANvidia Corp$24.37Mreported value+180.5K shares PRMEPrime Medicine, Inc.$23.65Mreported value+1.26M shares CMPSCompass Pathways Plc$11.04Mreported value+1.05M shares

Increased positions

EXASExact Sciences Corporation$162.77Mreported value+17.9K shares+0.4%CDNACaredx, Inc.$122.33Mreported value+1.75M shares+40.0%DNAGinkgo Bioworks Holdings, Inc.$106.05Mreported value+15.02M shares+63.0%VERVVerve Therapeutics, Inc.$89.10Mreported value+130.5K shares

Reduced positions

IONSIonis Pharmaceuticals, Inc.$141.68Mreported value-655.0K shares-17.0%TDOCTeladoc Health, Inc.$107.66Mreported value-134.7K shares-3.6%PACBPacific Biosciences of California, Inc.$98.72Mreported value-317.2K shares-2.6%NTLAIntellia Therapeutics, Inc.$90.80Mreported value

Exited positions

ONEM1life Healthcare Inc$30.98Mprior reported value-1.83M shares-100.0%ZYZymergen Inc.$19.21Mprior reported value-7.78M shares-100.0%CGENCompugen Ltd$4.24Mprior reported value-2.64M shares-100.0%